Skip to main content
. 2019 Jul 29;41(1):704–717. doi: 10.1080/0886022X.2019.1642210

Figure 1.

Figure 1.

The miR-193a (A), WT1 (B), or PODXL (C) expressions were compared between IMN patients and healthy controls. PODXL: podocalyxin; IMN: idiopathic membranous nephropathy. *p < .05 when compared with healthy controls; &p < .05 when compared with IMN patients at stage I; @p < .05 when compared with IMN patients at stage II.